1 / 17

BACTERIAL MENINGITIS

andrew
Download Presentation

BACTERIAL MENINGITIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. BACTERIAL MENINGITIS ALYSIA GIANI CHEM 4205

    3. What causes it? There are 3 main bacterial species that contribute to this disease: Haemophilus influenzae type b Neisseria meningitidis (Meningococcal) Streptococcus pneumoniae (Pneumococcal)

    4. How is it diagnosed? When patient presents symptoms of Meningitis, a sample of CSF is acquired from a spinal tap, which is then analyzed for bacterial presence.

    5. Bacterial Meningitis Facts There are 1.2 million cases annually worldwide, approximately 135,000 deaths. Bacterial meningitis is 1 of the top 10 infectious causes of death worldwide, according to the CDC. Half of survivors suffer neurological damage, and/or other permanent side effects.

    6. Haemophilus influenzae type b Affects about 13/1,000,000 children (2005), 3-4% are fatal. Infection has decreased drastically: From 4-10/10,000; since routine use of the Hib vaccine (since 1990) A major cause of lower respiratory tract infections in developing countries

    7. Neisseria meningitidis 5-50/1,000,000 people are infected worldwide every year. Most Deadly form of Bacterial Meningitis Humans are only host of bacteria, it is present in the nasopharynx 11-19% of people who have recovered suffer from permanent hearing loss, mental retardation, or other serious health problems. 10-14% of cases are fatal

    8. Streptococcus pneumoniae Infection rate in the U.S. has now decreased to 13/ 100,000, due to vaccination. (2002) Kills 14% of hospitalized adults with invasive disease. In some recovery cases, the patients sustain learning disabilities, and/or other impairments typical of meningitis, but less so than with other forms of meningitis. Overuse of antibiotics contributes to emerging drug resistance in this strain.

    9. Symptoms Most Common Fever Headache Stiff Neck Nausea & vomiting Sensitivity to light Confusion Sleepiness In Infants Inactivity Irritability Vomiting Poor feeding Advanced Disease Bruises develop under skin & spread rapidly Advanced Disease can lead to: Brain Damage Coma Death

    10. Symptoms

    11. Risk Factors Infants and young children Elderly College freshmen who live in dorms Patients without spleens People exposed to active or passive tobacco smoke. African Americans, American Indians, Alaskan Natives. People with underlying medical conditions (Ex. HIV & Sickle-cell disease)

    12. Treatment & Medication Antibiotics: Broad-Spectrum cephalosporin Ampicillin & Broad-Spectrum cephalosporin Vancomycin plus ceftazidime All antibiotics administered intravenously H. Influenzae & N. meningitidis- 7 days S. pneumoniae- 10-14 days

    13. Medications Continued N. meningitidis Chloramphenicol resistance Used in resource-limited settings (Sub-Saharan Africa). Stopped using in West because of very rare, yet serious side effect: Aplastic anemia. Very cheap synthesis Derived from bacteria- disrupts translation process by preventing peptide bond formation There are no non-pharmaceutical treatments for bacterial meningitis.

    14. Vaccines: H. influenzae type b Bacteria contains polysaccharide capsule Questions have arisen on the length of time the vaccine is effective. Cost of vaccine: $7.00 (typical vaccines are $1.00) The cost of this vaccine has limited their use in developing countries, even though this bacteria is a major cause of death.

    15. Vaccine: N. Meningitidis Meningococcal conjugate vaccine (MCV4) Price: $82; intramuscularly as single dose. Effective in all age groups Preferred over MPSV4 Meningococcal Polysaccharide Vaccine (MPSV4) Price: $86.10; subcutaneously as single dose. Re-administered every 3-5 years Age groups: Not under 2 and 11-12 years old

    16. Vaccine: S. Pneumoniae Bacteria contains polysaccharide capsule lactam resistance is common, resistance to multiple classes of drugs are increasing. 23-valent polysaccharide vaccine (Prevnar)- NEW $80.00 per dose Underused Supplies are inadequate New urinary antigen test may be useful in adults to identify if S. pneumoniae is present.

    17. Research for Paper Mechanism that causes the side effects and symptoms of bacterial meningitis and their role in cytokine response. Mechanism of antibiotics to specific bacteria and mechanisms of resistance by bacteria to antibiotics Interview Peter Hicks, Epidemiologist at the CDC.

More Related